These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Journal Abstract Search


277 related items for PubMed ID: 6329589

  • 1. Review of naltrexone, a long-acting opiate antagonist.
    Crabtree BL.
    Clin Pharm; 1984; 3(3):273-80. PubMed ID: 6329589
    [Abstract] [Full Text] [Related]

  • 2. The clinical pharmacology of naltrexone: pharmacology and pharmacodynamics.
    Verebey K.
    NIDA Res Monogr; 1981; 28():147-58. PubMed ID: 6791001
    [Abstract] [Full Text] [Related]

  • 3. Single- and multiple-dose pharmacokinetics of long-acting injectable naltrexone.
    Dunbar JL, Turncliff RZ, Dong Q, Silverman BL, Ehrich EW, Lasseter KC.
    Alcohol Clin Exp Res; 2006 Mar; 30(3):480-90. PubMed ID: 16499489
    [Abstract] [Full Text] [Related]

  • 4. [Limited role of naltrexone in the treatment of opiate addiction].
    van Brussel GH.
    Ned Tijdschr Geneeskd; 2001 Jul 28; 145(30):1452-6. PubMed ID: 11503313
    [Abstract] [Full Text] [Related]

  • 5. Naltrexone: a clinical perspective.
    Greenstein RA, Arndt IC, McLellan AT, O'Brien CP, Evans B.
    J Clin Psychiatry; 1984 Sep 28; 45(9 Pt 2):25-8. PubMed ID: 6469933
    [Abstract] [Full Text] [Related]

  • 6. In vivo and in vitro potency studies of 6beta-naltrexol, the major human metabolite of naltrexone.
    Porter SJ, Somogyi AA, White JM.
    Addict Biol; 2002 Apr 28; 7(2):219-25. PubMed ID: 12006217
    [Abstract] [Full Text] [Related]

  • 7. The sequential use of clonidine and naltrexone in the treatment of opiate addicts.
    Gold MS, Dackis CA, Washton AM.
    Adv Alcohol Subst Abuse; 1984 Apr 28; 3(3):19-39. PubMed ID: 6388273
    [Abstract] [Full Text] [Related]

  • 8. Naltrexone in addicted business executives and physicians.
    Washton AM, Pottash AC, Gold MS.
    J Clin Psychiatry; 1984 Sep 28; 45(9 Pt 2):39-41. PubMed ID: 6088468
    [Abstract] [Full Text] [Related]

  • 9. The role of the National Institute on Drug Abuse in the development of naltrexone.
    Ginzburg HM, Glass WJ.
    J Clin Psychiatry; 1984 Sep 28; 45(9 Pt 2):4-6. PubMed ID: 6088469
    [Abstract] [Full Text] [Related]

  • 10. Bioequivalence, dose-proportionality, and pharmacokinetics of naltrexone after oral administration.
    Meyer MC, Straughn AB, Lo MW, Schary WL, Whitney CC.
    J Clin Psychiatry; 1984 Sep 28; 45(9 Pt 2):15-9. PubMed ID: 6469932
    [Abstract] [Full Text] [Related]

  • 11. Naltrexone treatment in a jail work-release program.
    Brahen LS, Henderson RK, Capone T, Kordal N.
    J Clin Psychiatry; 1984 Sep 28; 45(9 Pt 2):49-52. PubMed ID: 6469937
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. [Ultra-rapid detoxification of opiate dependent patients: review of the literature, critiques and proposition for an experimental protocol].
    Fontaine E, Godfroid IO, Guillaume R.
    Encephale; 2001 Sep 28; 27(2):187-93. PubMed ID: 11407272
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Testing of drug delivery systems for use in the treatment of narcotic addiction.
    Reuning RH, Malspeis L, Frank S, Notari RE.
    Natl Inst Drug Abuse Res Monogr Ser; 1975 Sep 28; (4):43-5. PubMed ID: 827709
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Naltrexone implants can completely prevent early (1-month) relapse after opiate detoxification: a pilot study of two cohorts totalling 101 patients with a note on naltrexone blood levels.
    Foster J, Brewer C, Steele T.
    Addict Biol; 2003 Jun 28; 8(2):211-7. PubMed ID: 12850780
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]


    Page: [Next] [New Search]
    of 14.